<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221016056202N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-23</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Comparing  curcumin mediated photodynamic therapy and topical corticosteroid in tratment of oral  OLP</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the therapeutic effects of curcumin mediated photodynamic therapy and topical corticosteroid in tratment of erosive OLP</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>14</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66406</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Each patient with bilateral erosive OLP included in the study will be considered as follows: one side of the lesion will be the case and the other side will be the control lesion. . The experimental and control side of each patient is randomly selected using randomized blocks. Each block was considered with 4 allocations, including 2 allocations for the intervention and 2 allocations for the control group. Six possible sequences of treatment allocation are listed in each block, each written on a card. Each time a block was selected and the treatment sequence was recorded until treatment allocation was completed for all 7 participants. Randomization will be done by the methodologist. Allocation concealment will be performed by the principal investigator. A sequence is written on each of the 14 cards and sealed. Pockets are placed in a box. An envelope will be assigned to each participant based on the order of registration, Blinding description: The main researcher, who is responsible for examining and evaluating the lesions before and after the intervention, is unaware of which of the bilateral lesions of the patients is the case or the control. Another researcher is responsible for conducting the therapeutic intervention. The patients   do not know which lesions are in the case or control group. The statistician who performs the data analysis is unaware of the case group and control.As a result, the study will be triple blind.</study_design>
      <phase>3</phase>
      <hc_freetext>oral lichen planus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In each photodynamic therapy session  Sinanomin 1%( Topical gel contains %1 curcumin as nanoliposome  from Exir Nanosina company  will applied for 10 minutes in the side that is randomly selected as the case. After that a light cure device will be applied for irradiation with a blue light emitting wavelength of 470 nm for 5 min. Intervention 2: Control group: The other side of each patient that is considered as the control side with receive a placebo irradiation for 5 minutes with no light.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is I have decided to publish the article in domestic or foreign magazines. Complete information will be accessible in this way</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hanieh Farahmand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bagh Hoz Street, 6 Salah Building</address>
        <city>shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>71868-96754</zip>
        <telephone>+98 917 104 5288</telephone>
        <email>h_farahmand@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hanieh Farahmand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Baghe hoze</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>71868-96754</zip>
        <telephone>+98 917 103 5288</telephone>
        <email>h_farahmand@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Clinical diagnosis of OLP by 2 oral medicine specialists
Presence of bilateral errosive  symptomatic lesions
Patients willing to actively participate in the study
Patients that are capable of performing the exact instructions of the treatment protocol.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Age &lt; 18 years
Pregnancy or lactation
Uncontrolled systemic diseases (hepatopathies, coagulopathies,auto immune or haematological diseases)
History of allergic reactions to the active ingredient (curcumin) used in the clinical trial
Presence of histological signs of dysplasia in the biopsy specimen
Evidence of lichenoid lesions due to specific causes (dental materials, use of drugs inducing lichenoid reactions such as hypertensive or diabetic medications, etc.)
Smokers or heavy drinkers of alcohol.
Diabetic patients
Patients with photosensivity
Lichenoid reaction</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L43</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Lichen planus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In each photodynamic therapy session  Sinanomin 1%( Topical gel contains %1 curcumin as nanoliposome  from Exir Nanosina company  will applied for 10 minutes in the side that is randomly selected as the case. After that a light cure device will be applied for irradiation with a blue light emitting wavelength of 470 nm for 5 min.</i_keyword>
      <i_keyword>Control group: The other side of each patient that is considered as the control side with receive a placebo irradiation for 5 minutes with no light.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: days 0 and 7 and 14 and 28 and 56. Method of measurement: visual analogue scale.</prim_outcome>
      <prim_outcome>Size of lesion. Timepoint: days 0 and 7 and 14 and 28 and 56. Method of measurement: Digital caliper.</prim_outcome>
      <prim_outcome>Clinical manifestations of inflammation. Timepoint: days 0 and 7 and 14 and 28 and 56. Method of measurement: Thongprasom sign scoring.</prim_outcome>
      <prim_outcome>Clinical Efficacy of treatment. Timepoint: days 0 and 7 and 14 and 28 and 56. Method of measurement: REU.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Allergy to curcumin. Timepoint: days 1 and 3 and 5. Method of measurement: Observe the side effects of increased sensitivity.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Research Vice President of Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-08-31</approval_date>
        <contact_name>Research Ethics Committees of School of Dentistry- Shiraz University of Medical Sciences</contact_name>
        <contact_address>Zand Street, Namazi Square, Shiraz University of Medical Sciences shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
